Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Greece

Research and Innovation Action · Running

ELMUMY Elucidation of risk factors and health determinants associated with PROGRESSION of Monoclonal Gammopathies to Multiple Myeloma

Coordinator
Ethniko Kai Kapodistriako Panepistimio Athinon, Greece
Runs
1 January 2023 to 31 December 2026
Status
Running
EU funding
€10.0m
Total cost
€10.0m
Partners
14 organisations in 6 countries
Type
Research and Innovation Action
Grant agreement
101097094

What the project is doing

In the project's own words, from its summary on CORDIS.

Multiple Myeloma is a chronic malignancy characterized by slow progression and recurrences. Currently there is no effective cure since eventually the disease develops resistance to all the available therapeutic approaches. Although recent advances have expanded our understanding of the cellular functions associated with health to disease transition, recurrence and response to therapy, critical aspects of this complex pathology remain to be elucidated.

Application of omics technologies, and bioinformatics approaches on highly annotated samples obtained from all informative states (monoclonal gammopathy of undetermined significance [MGUS], smoldering MM [sMM], active MM [MM]) could identify biological pathways and molecules responsible for the onset, progression and resistance to therapy of Multiple Myeloma. In parallel, particular emphasis will be given to elucidating the health determinants and risk factors associated with progression to active MM from MGUS/sMM by using extensive demographic, lifestyle and exposure datasets.

MGUS is present in 3-5% of the ageing European population and every year, 1% progress to incurable MM that imposes a significant burden on EU societies and health systems. Thus, the best chances of curing MM may be in preventing its progression in the first place. Moreover, there is need of experimental models that recapitulate myeloma progression. We propose an interdisciplinary approach bringing together clinicians and researchers aiming to integrate epidemiological, clinical and experimental datasets in order to create a molecular model of cellular processes associated with the onset of active MM and response to therapy.

The proposed systems medicine approach could yield clinically actionable molecular features that could improve MM patient management. Moreover, the integration of lifestyle, clinical and omics information will provide specific profiles for each patient allowingpersonalized diagnosis, prevention, and therapeutic approaches. This action is part of the Cancer Mission cluster of projects on ''Understanding'.

Who is involved

OrganisationCityCountryRole
Ethniko Kai Kapodistriako Panepistimio AthinonAthinaGreeceCoordinator
Kypriako Idryma Erevnon Gia Ti Myiki DistrofiaAgios DometiosCyprusParticipant
Gottfried Wilhelm Leibniz Universitaet HannoverHannoverGermanyParticipant
Mosaiques Diagnostics GmbHHannoverGermanyParticipant
Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-UniversitatWurzburgGermanyParticipant
Ethniko Idryma ErevnonAthinaGreeceParticipant
Exelixis Diacheirisi Erevnas Kai Epikoinonia EeGerakas AttikiGreeceParticipant
Idryma Iatroviologikon Ereunon Akademias AthinonAthinaGreeceParticipant
Atos It Solutions and Services Iberia SLMadridSpainParticipant
Atos Spain SAMadridSpainThird party
Universidad De NavarraPamplonaSpainParticipant
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Universite De MontpellierMontpellierFranceThird party
Universita Degli Studi Di TorinoTorinoItalyParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI